logo
Plus   Neg
Share
Email

Amgen Drug Shrinks 54% Of Lung Cancer Tumors In Study

Amgen (AMGN) announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. Thirteen of the evaluable patients received the target dose of 960 mg once daily, of which seven (54%) achieved a partial response at one or more timepoints and six (46%) achieved stable disease, for a disease control rate of 100%.

AMG 510 is a first-in-class investigational oral therapy that is designed to selectively and irreversibly target the KRASG12C protein.

The company noted that the additional follow-up in a larger group of patients with non-small cell lung cancer (NSCLC) continued to show anti-tumor activity with no dose-limiting toxicities.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Swiss food giant Nestle SA said it is committed to achieving zero net greenhouse gas emissions by 2050, noting that climate change is one of the biggest threats faced by the world. As part of its efforts to achieve the goal, Nestle said it will launch more plant-based food and beverage options that are more environment friendly. Coffee giant Starbucks Corp. is set to open the world's largest Starbucks Reserve Roastery on November 15 on Chicago's Magnificent Mile. It will open in an interactive four-storey glass-clad building in 43,000 square feet space, employing about 200 people. The site at the corner of North Michigan Avenue and Erie Street was previously occupied by Crate & Barrel. United Parcel Service Inc. agreed to pay $8.4 million to the United States to settle allegations that it overcharged federal agencies for package delivery services, the U.S. Justice Department said. Under a General Services Administration or GSA contract, UPS was required to provide GSA with certain lower prices for its services.
Follow RTT